Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(5)
•••
Comment by roadking08on Aug 10, 2016 9:40pm
122 Views
Post# 25129034

RE:RE:RE:RE:Has biOasis done any primate studies with Mtf or Mtfp?

RE:RE:RE:RE:Has biOasis done any primate studies with Mtf or Mtfp?Regardless, I ask for a private placement for the only reason ithat it's a missing link at all my past winners that i had in the past, not saying for a minute they need one.but if I see one and we should not see one then......history repeats itself.
Warrants and options went to high exects and board members, private placements went to friend & family. Bashes arrived, newbies showed up by the handful along with a lot more post and other things my checked boxes have checked off including another common denominator, taking a lot more time than I thought. 
Would get into the low ball offer issue, but not tonight, that one robbed me a couple of times and pretty scared it could be an issue on this too.but let's hope not.
Greed, my age has tought me that whether it's a stock or whether it's after a funeral, greed is a true test of humanity. Some people rise up and some sink to the bottom just like here.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities